Equities research analysts predict that Novavax, Inc. (NASDAQ:NVAX) will report earnings of ($0.14) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Novavax’s earnings, with estimates ranging from ($0.15) to ($0.13). Novavax reported earnings of ($0.16) per share during the same quarter last year, which would indicate a positive year over year growth rate of 12.5%. The firm is scheduled to issue its next quarterly earnings results on Monday, May 14th.
According to Zacks, analysts expect that Novavax will report full year earnings of ($0.54) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0.42). For the next financial year, analysts forecast that the company will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.76) to ($0.34). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Novavax.
Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The company had revenue of $10.40 million during the quarter, compared to the consensus estimate of $7.98 million. During the same period in the previous year, the firm posted ($0.21) earnings per share. The company’s revenue was up 92.6% compared to the same quarter last year.
Several large investors have recently bought and sold shares of the company. MetLife Investment Advisors LLC bought a new stake in shares of Novavax in the 4th quarter valued at approximately $172,000. Teachers Advisors LLC raised its holdings in shares of Novavax by 17.2% in the fourth quarter. Teachers Advisors LLC now owns 583,645 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 85,611 shares during the period. California State Teachers Retirement System raised its holdings in shares of Novavax by 8.3% in the fourth quarter. California State Teachers Retirement System now owns 492,492 shares of the biopharmaceutical company’s stock worth $611,000 after buying an additional 37,793 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Novavax in the fourth quarter worth approximately $215,000. Finally, Deutsche Bank AG raised its holdings in shares of Novavax by 6.3% in the fourth quarter. Deutsche Bank AG now owns 2,567,169 shares of the biopharmaceutical company’s stock worth $3,182,000 after buying an additional 152,974 shares during the period. 39.22% of the stock is owned by institutional investors and hedge funds.
NVAX stock opened at $2.13 on Wednesday. Novavax has a one year low of $0.73 and a one year high of $2.75. The company has a market capitalization of $742.48, a P/E ratio of -3.38 and a beta of 2.50. The company has a debt-to-equity ratio of -3.12, a quick ratio of 2.76 and a current ratio of 2.76.
TRADEMARK VIOLATION WARNING: This article was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2018/03/21/analysts-anticipate-novavax-inc-nvax-will-post-earnings-of-0-14-per-share.html.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.